The Japan Clinical Oncology Group is currently conducting the JCOG1701 trial (SAVE study), a randomized controlled phase III trial that aimed to evaluate the non-inferiority of treatment suspension to continued treatment in NSCLC patients who have benefited from anti-PD-1/PD-L1 antibody treatment for at least 12 months (138). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.